Bioavailability Study for New Atorvastatin Formulation

Phase 4 Completed 12 enrolled Viatris Inc.

RandomizedCrossoverOpen-labelOther

Summary

The purpose of this study is to estimate the relative bioavailability of the commercial tablet with one prototype extemporaneous preparation suspension formulation, to assist with internal decision making on formulation development.

Timeline

Start: 2008-02
Primary completion: 2008-03
Completion: 2008-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Atorvastatin	Small molecule	80 mg	—

Bioavailability Study for New Atorvastatin Formulation

Summary

Timeline

Drugs

Indications